B-cell responses to vaccination at the extremes of age

Departments of Pathology-Immunology and Pediatrics, WHO Collaborative Center for Neonatal Vaccinology, Medical Faculty of University of Geneva, Centre Medical Universitaire, Geneva 4, Switzerland.
Nature Reviews Immunology (Impact Factor: 34.99). 04/2009; 9(3):185-94. DOI: 10.1038/nri2508
Source: PubMed


Infants and the elderly share a high vulnerability to infections and therefore have specific immunization requirements. Inducing potent and sustained B-cell responses is as challenging in infants as it is in older subjects. Several mechanisms to explain the decreased B-cell responses at the extremes of age apply to both infants and the elderly. These include intrinsic B-cell limitations as well as numerous microenvironmental factors in lymphoid organs and the bone marrow. This Review describes the mechanisms that shape B-cell responses at the extremes of age and how they could be taken into account to design more effective immunization strategies for these high-risk age groups.

Download full-text


Available from: Richard Aspinall,
    • "The current understanding for generation of robust antibodies from B cells requires 'help' from T helper cells in the form of cytokines, in particular Th2 cytokines (i.e. IL-4, IL-5, IL-6, IL-9, IL-10, IL-13) to assist in maturation of naïve B cells into effector cells (plasma cells) and memory B cells [59]. This is likely the case for HPV vaccination for the generation of long-lived HPV-specific B cell memory responses for long-term protection. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil(®) and Cervarix(®) vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vagina cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil(®) vaccine also offer additional protection against anal cancer precursors. However, high costs of HPV vaccines and the logistics of delivering a three-dose schedule over 6 months are challenging in countries with limited resources. Several studies have demonstrated non-inferiority in antibody response between adolescents (9-15 years old) who received two doses (6 months apart) and women (>15 years old) who received the standard three-dose schedule. These studies provided evidence for the World Health Organization and European Medical Association to revise its recommendation to give two instead of three doses of HPV vaccine to adolescents below 15 years of age, provided the 2nd dose is given 6 months apart. Although reduced dose schedules can alleviate costs and logistics associated with HPV vaccination, especially in resource-poor countries, there are still gaps in this area of research, particularly regarding long-term protection. This review discusses the findings on antibody response and clinical outcomes in studies evaluating reduced dose HPV schedules, and highlights the important considerations of its implementation. In addition, other important immunological biomarkers that may be associated with long-term protection are highlighted and discussed. Copyright © 2015. Published by Elsevier Ltd.
    Vaccine 08/2015; 33(39). DOI:10.1016/j.vaccine.2015.07.102 · 3.62 Impact Factor
  • Source
    • "A number of studies have determined that the immaturity of the immune system is most pronounced after birth and is overcome as the child develops. The immaturity (inability to fully respond to an antigenic stimulus) of the neonatal immune system has been observed in humans (1) and a number of other species, e.g., pig (2), cow (3, 4), and horse (5), and in experimental rodent models like mouse (1), rat (6), and cotton rat (7, 8). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neonates have an immature immune system, which cannot adequately protect against infectious diseases. Early in life, immune protection is accomplished by maternal antibodies transferred from mother to offspring. However, decaying maternal antibodies inhibit vaccination as is exemplified by the inhibition of seroconversion after measles vaccination. This phenomenon has been described in both human and veterinary medicine and is independent of the type of vaccine being used. This review will discuss the use of animal models for vaccine research. I will review clinical solutions for inhibition of vaccination by maternal antibodies, and the testing and development of potentially effective vaccines. These are based on new mechanistic insight about the inhibitory mechanism of maternal antibodies. Maternal antibodies inhibit the generation of antibodies whereas the T cell response is usually unaffected. B cell inhibition is mediated through a cross-link between B cell receptor (BCR) with the Fcγ-receptor IIB by a vaccine-antibody complex. In animal experiments, this inhibition can be partially overcome by injection of a vaccine-specific monoclonal IgM antibody. IgM stimulates the B cell directly through cross-linking the BCR via complement protein C3d and antigen to the complement receptor 2 (CR2) signaling complex. In addition, it was shown that interferon alpha binds to the CD21 chain of CR2 as well as the interferon receptor and that this dual receptor usage drives B cell responses in the presence of maternal antibodies. In lieu of immunizing the infant, the concept of maternal immunization as a strategy to protect neonates has been proposed. This approach would still not solve the question of how to immunize in the presence of maternal antibodies but would defer the time of infection to an age where infection might not have such a detrimental outcome as in neonates. I will review successful examples and potential challenges of implementing this concept.
    Frontiers in Immunology 09/2014; 5:446. DOI:10.3389/fimmu.2014.00446
  • Source
    • "The finding that TFH cells are present and functional in early life, although in a limited extent compared to adults, is of interest to improve neonatal and pediatric vaccines. Indeed, in the context of defective follicular DCs and B-cells, the other partners of humoral immunity, in newborns (88), early priming of neonatal TFH cells could promote the induction of high-affinity antibody responses when the other cellular actors become functional. Interestingly, administration of a CpG-adjuvanted vaccine in mouse neonates circumvented the limited expansion and development in GC TFH cells of neonatal TFH cells (87), suggesting that this could represent a beneficial strategy for efficient vaccination of newborns. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In comparison to adults, newborns display a heightened susceptibility to pathogens and a propensity to develop allergic diseases. Particular properties of the neonatal immune system can account for this sensitivity. Indeed, a defect in developing protective Th1-type responses and a skewing toward Th2 immunity characterize today the neonatal T-cell immunity. Recently, new findings concerning Th17, regulatory helper T-cell, and follicular helper T-cell subsets in newborns have emerged. In some circumstances, development of effector inflammatory Th17-type responses can be induced in neonates, while differentiation in regulatory T-cells appears to be a default program of neonatal CD4(+) T-cells. Poor antibody production, affinity maturation, and germinal center reaction in vaccinated neonates are correlated with a limiting expansion of TFH lymphocytes. We review herein the factors accounting for and the implications of the unbalanced neonatal helper T-cell immunity.
    Frontiers in Immunology 08/2014; 5:393. DOI:10.3389/fimmu.2014.00393
Show more